These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 27566701)

  • 1. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
    Saif MW; Knost JA; Chiorean EG; Kambhampati SR; Yu D; Pytowski B; Qin A; Kauh JS; O'Neil BH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):815-24. PubMed ID: 27566701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
    Cole CB; Morelli MP; Fantini M; Miettinen M; Fetsch P; Peer C; Figg WD; Yin T; Houston N; McCoy A; Lipkowitz S; Zimmer A; Lee JM; Pavelova M; Villanueva EN; Trewhitt K; Solarz BB; Fergusson M; Mavroukakis SA; Zaki A; Tsang KY; Arlen PM; Annunziata CM
    J Exp Clin Cancer Res; 2023 Mar; 42(1):76. PubMed ID: 36991390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
    Khalil DN; Postow MA; Ibrahim N; Ludwig DL; Cosaert J; Kambhampati SR; Tang S; Grebennik D; Kauh JS; Lenz HJ; Flaherty KT; Hodi FS; Lawrence DP; Wolchok JD
    Clin Cancer Res; 2016 Nov; 22(21):5204-5210. PubMed ID: 27797971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
    Rosen LS; Hurwitz HI; Wong MK; Goldman J; Mendelson DS; Figg WD; Spencer S; Adams BJ; Alvarez D; Seon BK; Theuer CP; Leigh BR; Gordon MS
    Clin Cancer Res; 2012 Sep; 18(17):4820-9. PubMed ID: 22767667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
    de Bono J; Lin CC; Chen LT; Corral J; Michalarea V; Rihawi K; Ong M; Lee JH; Hsu CH; Yang JC; Shiah HS; Yen CJ; Anthoney A; Jove M; Buschke S; Fuertig R; Schmid U; Goeldner RG; Strelkowa N; Huang DC; Bogenrieder T; Twelves C; Cheng AL
    Br J Cancer; 2020 Apr; 122(9):1324-1332. PubMed ID: 32161368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors.
    Cole CB; Morelli MP; Fantini M; Miettinen M; Fetsch P; Peer C; Figg WD; Yin T; Houston N; McCoy A; Lipkowitz S; Zimmer A; Lee JM; Pavelova M; Villanueva EN; Trewhitt K; Solarz BB; Fergusson M; Mavroukakis SA; Zaki A; Tsang KY; Arlen PM; Annunziata CM
    J Exp Clin Cancer Res; 2023 Apr; 42(1):102. PubMed ID: 37101182
    [No Abstract]   [Full Text] [Related]  

  • 7. A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.
    Tolcher AW; Berlin JD; Cosaert J; Kauh J; Chan E; Piha-Paul SA; Amaya A; Tang S; Driscoll K; Kimbung R; Kambhampati SR; Gueorguieva I; Hong DS
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):673-680. PubMed ID: 28280971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II/III Study of Radiofrequency Ablation Combined with Cytokine-Induced Killer Cells Treating Colorectal Liver Metastases.
    Li X; Dai X; Shi L; Jiang Y; Chen X; Chen L; Zhao J; Qiang W; Wu J; Ji M; Jiang J; Wu C
    Cell Physiol Biochem; 2016; 40(1-2):137-145. PubMed ID: 27855365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial Metabolic Control of Lymphangiogenesis.
    Yu P; Wu G; Lee HW; Simons M
    Bioessays; 2018 Jun; 40(6):e1700245. PubMed ID: 29750374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipopolysaccharide increases the release of VEGF-C that enhances cell motility and promotes lymphangiogenesis and lymphatic metastasis through the TLR4- NF-κB/JNK pathways in colorectal cancer.
    Zhu G; Huang Q; Huang Y; Zheng W; Hua J; Yang S; Zhuang J; Wang J; Ye J
    Oncotarget; 2016 Nov; 7(45):73711-73724. PubMed ID: 27713159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.
    Fankhauser M; Broggi MAS; Potin L; Bordry N; Jeanbart L; Lund AW; Da Costa E; Hauert S; Rincon-Restrepo M; Tremblay C; Cabello E; Homicsko K; Michielin O; Hanahan D; Speiser DE; Swartz MA
    Sci Transl Med; 2017 Sep; 9(407):. PubMed ID: 28904226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.
    Leitch IM; Gerometta M; Eichenbaum D; Finger RP; Steinle NC; Baldwin ME
    Ophthalmol Ther; 2024 Jul; 13(7):1857-1875. PubMed ID: 38824253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homodimeric peptide radiotracer [
    Chen X; Zhang Z; Wang L; Zhang J; Zhao T; Cai J; Dang Y; Guo R; Liu R; Zhou Y; Wei R; Lou X; Xia F; Ma D; Li F; Dai J; Li F; Xi L
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2338-2352. PubMed ID: 38411667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers.
    Lin S; Chai Y; Zheng X; Xu X
    Mol Biol Rep; 2023 Dec; 51(1):14. PubMed ID: 38085375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphatics in the liver for translational science.
    Iwakiri Y
    Clin Liver Dis (Hoboken); 2023 Apr; 21(4):122-124. PubMed ID: 37936952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis-An Emerging Role in Organ Fibrosis.
    Wang D; Zhao Y; Zhou Y; Yang S; Xiao X; Feng L
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis.
    Vimalraj S; Hariprabu KNG; Rahaman M; Govindasami P; Perumal K; Sekaran S; Ganapathy D
    3 Biotech; 2023 Oct; 13(10):326. PubMed ID: 37663750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy.
    Paillasse MR; Esquerré M; Bertrand FA; Poussereau-Pomié C; Pichery M; Visentin V; Gueguen-Dorbes G; Gaujarengues F; Barron P; Badet G; Briaux A; Ancey PB; Sibrac D; Erdociain E; Özcelik D; Meneyrol J; Martin V; Gomez-Brouchet A; Selves J; Rochaix P; Battistella M; Lebbé C; Delord JP; Dol-Gleizes F; Bono F; Blanc I; Alam A; Hunneyball I; Whittaker M; Fons P
    Cancer Res Commun; 2022 Nov; 2(11):1504-1519. PubMed ID: 36970050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lymphatic Endothelium in the Context of Radioimmuno-Oncology.
    Suárez L; Rodríguez-Ruiz ME; Rouzaut A
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612017
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.